Elysium Health   Report issue

For profit Phase 1 Phase 2
Founded: New York NY United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02678611
First Marketed Drug
2017
cyproheptadine (periactin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ELYSIUM | Elysium Health | Elysium Health, Inc.